| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Merck & Company Inc. | ODM-208 - (CYPIDES) | Metastatic Castration-Resistant Prostate (mCRPC) Cancer | Phase 2 | oral | Oncology | |
| Merck & Company Inc. | MK-2060 | End-stage renal disease (ESRD) patients receiving hemodialysis | Phase 2 | Intravenous | N/A | |
| Merck & Company Inc. | NKTR-255 with BAVENCIO (avelumab) - (JAVELIN) | Locally advanced or metastatic urothelial carcinoma (UC) | Phase 2 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | REBLOZYL (Luspatercept) - (COMMANDS) | Non-transfusion-dependent beta-thalassemia | Phase 2 | Data Released | Subcutaneous injection | Genetic Disorder |
| Merck & Company Inc. | REBLOZYL (Luspatercept) - (COMMANDS) | Non-transfusion-dependent beta-thalassemia | Phase 2 | Data Released | Subcutaneous injection | Genetic Disorder |
| Merck & Company Inc. | MRx0518 with bavencio (avelumab) | 1L Urothelial carcinoma | Phase 2 | Intravenous | Oncology | |
| Merck & Company Inc. | INT230-6 with Keytruda | Pancreatic, Colon, Bile Duct and Squamous Cell Cancer | Phase 2 | intratumoral and intravenous | Oncology | |
| Merck & Company Inc. | PRA023 - (ATHENA-SSc-ILD) | Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) | Phase 2 | Ongoing | Intravenous | Respiratory |